Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Macupatide - Eli Lilly and Company /

Next Previous
Drug Profile

Macupatide - Eli Lilly and Company /

Alternative Names: LAGIPRA; LY 3532226

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antihyperglycaemics; Obesity therapies
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Obesity; Type 1 diabetes mellitus
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 10 Oct 2025 Eli Lilly and Company plans a phase II trial for Obesity and Type II diabetes mellitus (Combination therapy, Monotherapy) in Argentina, Australia, Puerto Rico and the US in November 2025 (NCT07215559)
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(Combination therapy) in Germany (SC)
  • 09 Sep 2024 Efficacy data from a phase I trial in Type 2 diabetes mellitus presented at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top